Trial Profile
A Phase III randomized clinical trial of Silmitasertib for Cholangiocarcinoma
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2021
Price :
$35
*
At a glance
- Drugs Silmitasertib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors Senhwa Biosciences
- 20 Jan 2021 New trial record
- 15 Jan 2021 According to a Senhwa Biosciences media release, a phase 3 trial is planned.